ワクチン市場：技術別（遺伝子組換え、トキソイド、コンジュゲート、RNA）、タイプ別（1価、多価）、疾患別（肺炎球菌、インフルエンザ、DTP、HPV、MMR、COVID-19）、投与経路別（IM、SC、経口）、エンドユーザー別（小児、成人）、地域別 - 2028年までの世界予測

Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) & Region - Global Forecast to 2028

世界のワクチン市場規模は、2023年の776億米ドルから2028年には938億米ドルに達すると予測され、予測期間中の年平均成長率は3.9%である。伝染病の高い発生率、ワクチン技術の革新、ワクチン開発に対する政府の支... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年11月8日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	371	380	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のワクチン市場規模は、2023年の776億米ドルから2028年には938億米ドルに達すると予測され、予測期間中の年平均成長率は3.9%である。伝染病の高い発生率、ワクチン技術の革新、ワクチン開発に対する政府の支援と多額の資金援助、ワクチン接種イニシアチブの拡大、革新的ワクチンへの投資と上市への強い注力といった要因が挙げられる。
「結合型ワクチン分野がワクチン市場で圧倒的なシェアを占める
世界のワクチン市場は、技術別に不活化・サブユニットワクチン、弱毒生ワクチン、トキソイドワクチン、ウイルスベクターワクチン、組み換えワクチン、結合型ワクチンに分類されます。コンジュゲートワクチンは大きなCAGRで成長すると予測される。政府支援の拡大、企業による結合型ワクチン開発分野への投資、官民間の協力関係の強化は、市場の成長にプラスの影響を与えそうです。

"肺炎球菌セグメントが2022年の疾患適応症セグメントで最大シェアを占める"
疾患適応症に基づき、ワクチン市場は、混合ワクチン、HPV、髄膜炎菌性疾患、帯状疱疹、ロタウイルス、MMR、肺炎球菌性疾患、インフルエンザ、水痘、肝炎、DTP、ポリオ、その他の疾患適応症に区分される。2022年には、肺炎球菌セグメントがワクチン市場で最大のシェアを占めた。肺炎球菌感染症患者の増加、ワクチン接種プログラムへの政府投資の増加など様々な要因により、同セグメントは市場で圧倒的なシェアを占めている。

「アジア太平洋地域は、ワクチン市場においてより速いペースで成長する可能性が高い。
ワクチン市場の地域は、北米、欧州、アジア太平洋、中南米、中東、アフリカに区分される。アジア太平洋地域は、予測期間中に大きなCAGRで成長すると予測されている。同地域の成長は、ワクチン開発に対する政府支援の増加、アジア諸国における医療支出の増加、伝染病の出現と再出現、可処分所得の増加などの恩恵を受け、アジア太平洋地域への投資を増やしている企業によるところが大きい。

本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給サイド80％、需要サイド20
- 指定（サプライサイド）別マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米40％、欧州25％、アジア太平洋地域20％、中南米10％、中東4％、アフリカ1
レポート掲載企業一覧
- GSK plc（英国）
- メルク社（米国）
- ファイザー（米国）
- サノフィ（フランス）
- CSL（オーストラリア）
- エマージェント（米国）
- ジョンソン・エンド・ジョンソン・サービス社（米国）
- アストラゼネカ（英国）
- Serum Institute of India Pvt.(インド）
- バイエルン・ノルディック（デンマーク）
- 田辺三菱製薬（日本）
- 第一三共株式会社（日本）
- パナセアバイオテック（インド）
- バイオロジカル・イー社（インド）
- バーラト・バイオテック（インド）
- ノババックス（米国）
- イノビオ・ファーマシューティカルズ（米国）
- シノバック（中国）
- インセプタ・ファーマシューティカルズ（バングラデシュ）
- バルネバSE(フランス)
- VBIワクチン社（米国）
- バイオファルマ（インドネシア）
- マイクロジェン社（ロシア）
- Zhi fei Biological（中国）
- Indian Immunologicals Ltd（インド）
調査範囲
本レポートは、ワクチン市場の詳細な情報を提供します。技術、タイプ、適応疾患、投与経路、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主な利点
本レポートは、ワクチン市場全体とそのサブセグメントにおける売上高に最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（新規ワクチンへの投資と上市の重視、感染症流行の増加、予防接種プログラムの拡大、ワクチン技術の進歩、ワクチン開発に対する政府の強力な支援と資金提供）、阻害要因（高い開発コスト、特許切れ）、機会（治療用ワクチンへの注目の高まり、強固で強力なパイプライン）、課題（規制プロセスの厳格化、ワクチン供給不足、頻繁な製品回収）が臨床試験用品市場の成長に影響を与えていることを分析しています。
- 製品開発/イノベーション：ワクチン市場の新発売製品に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域のワクチン市場を分析しています。
- 市場の多様化：ワクチン市場における新サービス、未開拓地域、最新動向、投資に関する詳細情報。
- パイプライン分析：臨床試験中の製品に関する包括的情報。
- 競合評価：GSK plc（英国）、Merck & Co., Inc.（米国）、Pfizer, Inc.（米国）、Sanofi（フランス）、CSL（オーストラリア）、Emergent（米国）、Johnson & Johnson Services Inc.（米国）、AstraZeneca（英国）、Serum Institute of India Pvt.(インド）、バイエルン・ノルディック（デンマーク）。

ページTOPに戻る

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 INCLUSIONS & EXCLUSIONS 45
1.4 MARKET SCOPE 45
1.4.1 MARKETS COVERED 45
1.4.2 REGIONS COVERED 46
1.4.3 YEARS CONSIDERED 46
1.4.4 CURRENCY CONSIDERED 46
1.5 RESEARCH LIMITATIONS 47
1.6 STAKEHOLDERS 47
1.7 SUMMARY OF CHANGES 48
1.8 RECESSION IMPACT: VACCINES MARKET 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.2 RESEARCH APPROACH 49
FIGURE 1 RESEARCH DESIGN 49
2.2.1 SECONDARY DATA 50
2.2.2 PRIMARY DATA 51
FIGURE 2 BREAKDOWN OF PRIMARIES 51
2.2.2.1 Primary insights 52
FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS 52
2.3 MARKET SIZE ESTIMATION 53
FIGURE 4 MARKET SIZE ESTIMATION: VACCINES MARKET, 2022 53
FIGURE 5 TOTAL REVENUE: VACCINES MARKET 54
FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022 54
2.3.1 SEGMENTAL ASSESSMENT 55
FIGURE 7 TOP-DOWN APPROACH 55
2.4 GROWTH RATE ASSUMPTIONS 57
FIGURE 8 CAGR PROJECTION: VACCINES MARKET 57
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 58
2.5 STUDY ASSUMPTIONS 58
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION 59
FIGURE 10 DATA TRIANGULATION METHODOLOGY 59
2.7 RISK ASSESSMENT 60

2.8 IMPACT OF RECESSION IN VACCINES MARKET 60
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 61
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 61
3 EXECUTIVE SUMMARY 62
FIGURE 11 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 62
FIGURE 12 VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 63
FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION) 64
FIGURE 14 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION) 65
FIGURE 15 VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 65
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET 66
4 PREMIUM INSIGHTS 68
4.1 VACCINES MARKET OVERVIEW 68
FIGURE 17 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 68
4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY AND COUNTRY, 2022 69
FIGURE 18 M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022 69
4.3 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 70
FIGURE 19 M-RNA VACCINES TO DOMINATE MARKET IN 2028 70
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET 70
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET 71
TABLE 4 IMPACT ANALYSIS: VACCINES MARKET 72
5.2.1 DRIVERS 72
5.2.1.1 Strong emphasis on launch of novel vaccines 72
5.2.1.2 Rising prevalence of infectious diseases 73
FIGURE 22 INCIDENCE OF TUBERCULOSIS IN US, 2017–2021 74
5.2.1.3 Increasing number of immunization programs 74
5.2.1.4 Advancements in vaccine technology 75
5.2.1.5 Robust government support and funding for vaccine development 75
TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 High cost of vaccine development 76

5.2.3 OPPORTUNITIES 77
5.2.3.1 Increased focus on therapeutic vaccines 77
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 77
5.2.4 CHALLENGES 78
5.2.4.1 Stringent regulatory processes 78
5.2.4.2 Frequent product recalls 78
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
FIGURE 23 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS 79
5.4 PRICING ANALYSIS 79
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 79
TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES 79
TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES 81
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 82
TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES 82
TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES 82
TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES 83
TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES 83
TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES 84
TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES 84
5.4.3 AVERAGE SELLING PRICE TREND 85
5.5 TECHNOLOGY ANALYSIS 85
5.6 VALUE CHAIN ANALYSIS 85
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 86
5.7 PIPELINE ANALYSIS 87
FIGURE 25 CLINICAL TRIALS IN VACCINES MARKET 87
FIGURE 26 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION 87
TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS 88
5.7.1 KEY PIPELINE PRODUCTS 91
TABLE 15 KEY PIPELINE VACCINES: GSK PL 91
TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC. 91
TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC. 91
TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A. 91
5.8 ECOSYSTEM MARKET/MAP 92
FIGURE 27 ECOSYSTEM MARKET/MAP 92
TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET 92
5.9 REGULATORY ANALYSIS 93
5.9.1 REGULATORY LANDSCAPE FOR VACCINES 93
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
5.10 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 26 PORTER’S FIVE FORCES ANALYSIS 98
5.10.1 THREAT OF NEW ENTRANTS 99
5.10.2 THREAT OF SUBSTITUTES 99
5.10.3 BARGAINING POWER OF SUPPLIERS 99
5.10.4 BARGAINING POWER OF BUYERS 99
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 99
5.11 PATENT ANALYSIS 100
FIGURE 28 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023 100
TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET 100
5.12 KEY CONFERENCES & EVENTS 101
TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024 101
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 102
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 102
5.13.2 KEY BUYING CRITERIA 103
FIGURE 30 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET 103
6 VACCINES MARKET, BY TECHNOLOGY 104
6.1 INTRODUCTION 105
TABLE 29 VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 105
6.2 CONJUGATE VACCINES 105
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET 105
TABLE 30 VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021–2028 (USD BILLION) 106
TABLE 31 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 32 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 33 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108
TABLE 34 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108

6.3 RECOMBINANT VACCINES 108
6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET 108
TABLE 35 EXAMPLES OF RECOMBINANT VACCINES 109
TABLE 36 VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2021–2028 (USD BILLION) 110
TABLE 37 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 38 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 39 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 40 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 112
6.4 INACTIVATED & SUBUNIT VACCINES 112
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET 112
TABLE 41 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 113
TABLE 42 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION, 2021–2028 (USD BILLION) 114
TABLE 43 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 114
TABLE 44 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 45 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 46 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 116
6.5 LIVE ATTENUATED VACCINES 116
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET 116
TABLE 47 EXAMPLES OF LIVE ATTENUATED VACCINES 117
TABLE 48 VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021–2028 (USD BILLION) 117
TABLE 49 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 50 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 51 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
TABLE 52 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
6.6 TOXOID VACCINES 119
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET 119
TABLE 53 EXAMPLES OF TOXOID VACCINES 120
TABLE 54 VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021–2028 (USD BILLION) 120
TABLE 55 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 56 EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
TABLE 58 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
6.7 VIRAL VECTOR VACCINES 123
6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 123
TABLE 59 VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION, 2021–2028 (USD BILLION) 123
TABLE 60 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 61 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 62 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
TABLE 63 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
6.8 M-RNA VACCINES 126
6.8.1 INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET 126
TABLE 64 VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021–2028 (USD BILLION) 127
TABLE 65 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 127
TABLE 66 EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 67 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 68 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 129
6.9 OTHER VACCINES 129
TABLE 69 VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021–2028 (USD BILLION) 130
TABLE 70 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 130
TABLE 71 EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 72 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 73 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 132

7 VACCINES MARKET, BY TYPE 133
7.1 INTRODUCTION 134
TABLE 74 VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 134
7.2 MONOVALENT VACCINES 134
7.2.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 134
TABLE 75 EXAMPLES OF MONOVALENT VACCINES 135
TABLE 76 VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 136
TABLE 77 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 136
TABLE 78 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 79 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 80 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 138
7.3 MULTIVALENT VACCINES 138
7.3.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET 138
TABLE 81 EXAMPLES OF MULTIVALENT VACCINES 139
TABLE 82 VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 140
TABLE 83 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 140
TABLE 84 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 85 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 86 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 142
8 VACCINES MARKET, BY DISEASE INDICATION 143
8.1 INTRODUCTION 144
TABLE 87 VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 144
8.2 PNEUMOCOCCAL DISEASE 144
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 144
TABLE 88 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 145
TABLE 89 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 146
TABLE 90 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 146
TABLE 91 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147

TABLE 92 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147
TABLE 93 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 148
8.3 INFLUENZA 148
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 148
TABLE 94 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 149
TABLE 95 VACCINES MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD BILLION) 150
TABLE 96 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 150
TABLE 97 EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 98 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 99 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 152
8.4 COMBINATION VACCINES 152
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET 152
TABLE 100 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 153
TABLE 101 VACCINES MARKET FOR COMBINATION VACCINES, BY REGION, 2021–2028 (USD BILLION) 154
TABLE 102 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 154
TABLE 103 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 104 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 105 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 156
8.5 HPV 156
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 156
TABLE 106 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 157
TABLE 107 VACCINES MARKET FOR HPV, BY REGION, 2021–2028 (USD BILLION) 158
TABLE 108 NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 158
TABLE 109 EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 110 ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 111 LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 160
8.6 MENINGOCOCCAL DISEASE 160
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET 160
TABLE 112 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 161
TABLE 113 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 161
TABLE 114 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 115 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
TABLE 117 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
8.7 HERPES ZOSTER 163
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 163
TABLE 118 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021–2028 (USD BILLION) 164
TABLE 119 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 120 EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
TABLE 122 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
8.8 ROTAVIRUS 166
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET 166
TABLE 123 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 167
TABLE 124 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021–2028 (USD BILLION) 167
TABLE 125 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 126 EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 127 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
TABLE 128 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
8.9 MMR 170
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET 170
TABLE 129 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 170
TABLE 130 VACCINES MARKET FOR MMR, BY REGION, 2021–2028 (USD BILLION) 171
TABLE 131 NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 171
TABLE 132 EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 133 ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 134 LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 173
8.10 VARICELLA 173
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET 173
TABLE 135 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 173
TABLE 136 VACCINES MARKET FOR VARICELLA, BY REGION, 2021–2028 (USD BILLION) 174
TABLE 137 NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 174
TABLE 138 EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 139 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 140 LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 176
8.11 HEPATITIS 176
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET 176
TABLE 141 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 177
TABLE 142 VACCINES MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 143 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 144 EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 145 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
TABLE 146 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
8.12 DTP 180
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET 180
TABLE 147 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 180
TABLE 148 VACCINES MARKET FOR DTP, BY REGION, 2021–2028 (USD BILLION) 181
TABLE 149 NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 181
TABLE 150 EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 151 ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 152 LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 183
8.13 POLIO 183
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 183
TABLE 153 VACCINES MARKET FOR POLIO, BY REGION, 2021–2028 (USD BILLION) 184
TABLE 154 NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 155 EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 156 ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
TABLE 157 LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
8.14 OTHER DISEASE INDICATIONS 186
FIGURE 31 NUMBER OF COVID-19 CASES IN US, 2020–2023 187
TABLE 158 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 187
TABLE 159 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD BILLION) 188
TABLE 160 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 188
TABLE 161 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 162 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 163 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 190
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 191
9.1 INTRODUCTION 192
TABLE 164 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 192
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 192
9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET 192
TABLE 165 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 193
TABLE 166 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 194
TABLE 167 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 194
TABLE 168 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 169 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 170 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 196
9.3 ORAL ADMINISTRATION 196
9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET 196
TABLE 171 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 197
TABLE 172 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 197
TABLE 173 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 174 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 175 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 199
9.4 OTHER ROUTES OF ADMINISTRATION 199
TABLE 176 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 200
TABLE 177 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 200
TABLE 178 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 179 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 180 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 202
10 VACCINES MARKET, BY END USER 203
10.1 INTRODUCTION 204
TABLE 181 VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 204
10.2 PEDIATRIC VACCINES 204
10.2.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET 204
TABLE 182 VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021–2028 (USD BILLION) 205
TABLE 183 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 184 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 185 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
TABLE 186 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
10.3 ADULT VACCINES 207
10.3.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD 207
TABLE 187 VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021–2028 (USD BILLION) 209
TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 209
TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 211
11 VACCINES MARKET, BY REGION 212
11.1 INTRODUCTION 213
TABLE 192 VACCINES MARKET, BY REGION, 2021–2028 (USD BILLION) 213
11.2 NORTH AMERICA 213
FIGURE 32 NORTH AMERICA: VACCINES MARKET SNAPSHOT 214
TABLE 193 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 215
TABLE 194 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 215
TABLE 195 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 216
TABLE 196 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 216
TABLE 197 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 217
TABLE 198 NORTH AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 217
11.3 NORTH AMERICA: RECESSION IMPACT 217
11.3.1 US 218
11.3.1.1 US to dominate North American vaccines market during forecast period 218
TABLE 199 US: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 219
TABLE 200 US: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 219
TABLE 201 US: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 220
TABLE 202 US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 220
TABLE 203 US: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 221
11.3.2 CANADA 221
11.3.2.1 High incidence of infectious diseases to drive market 221
TABLE 204 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 222
TABLE 205 CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 222
TABLE 206 CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 223
TABLE 207 CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 223
TABLE 208 CANADA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 224
11.4 EUROPE 224
TABLE 209 EUROPE: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 224
TABLE 210 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 225
TABLE 211 EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 225
TABLE 212 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 226
TABLE 213 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 226
TABLE 214 EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 227
11.5 EUROPE: RECESSION IMPACT 227
11.5.1 GERMANY 227
11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market 227
TABLE 215 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 229
TABLE 216 GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 229
TABLE 217 GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 230
TABLE 218 GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 230
TABLE 219 GERMANY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 231
11.5.2 UK 231
11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market 231
TABLE 220 UK: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 232
TABLE 221 UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 232
TABLE 222 UK: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 233
TABLE 223 UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 233
TABLE 224 UK: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 234
11.5.3 FRANCE 234
11.5.3.1 Favorable government initiatives for mass immunization to drive market 234
TABLE 225 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 235
TABLE 226 FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 235
TABLE 227 FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 236
TABLE 228 FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 236
TABLE 229 FRANCE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 237
11.5.4 ITALY 237
11.5.4.1 Higher investments by companies for increased production capacities to drive market 237
TABLE 230 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 238
TABLE 231 ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 238
TABLE 232 ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 239
TABLE 233 TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 239
TABLE 234 ITALY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 240
11.5.5 SPAIN 240
11.5.5.1 Rising investments in vaccine development by private organizations to drive market 240
TABLE 235 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 241
TABLE 236 SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 241
TABLE 237 SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 242
TABLE 238 SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 242
TABLE 239 SPAIN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 243
11.5.6 REST OF EUROPE 243
TABLE 240 REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 244
TABLE 241 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 244
TABLE 242 REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 245
TABLE 243 REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 245
TABLE 244 REST OF EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 246
11.6 ASIA PACIFIC 246
FIGURE 33 ASIA PACIFIC: VACCINES MARKET SNAPSHOT 247
TABLE 245 ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 248
TABLE 246 ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 248
TABLE 247 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 249
TABLE 248 ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 249
TABLE 249 ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 250
TABLE 250 ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 250

ページTOPに戻る

Table of Contents

Summary

The global vaccines market size is projected to reach USD 93.8 billion by 2028 from USD 77.6 billion in 2023, at a CAGR of 3.9% during the forecast period. Factors such as high incidence of contagious diseases, innovation in vaccine technology, governmental support & substantial funding for vaccine development, growing vaccination initiatives and strong focus on investing and launching innovative vaccines.
“The conjugate vaccines segment held the dominant share in the vaccines market”
Based on technology, the global vaccines market is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, viral vector vaccines, recombinant vaccines and conjugate vaccines. The conjugate vaccines segment is anticipated to grow at significant CAGR. Growing governmental support coupled with investment by companies in the field of conjugate vaccine development, increasing collaboration between public and private sectors are likely to have positive impact on the growth of the market.

“Pneumococcal segment accounted for the largest share of the disease indication segment in 2022.”
Based on disease indication, the vaccines market is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment accounted for the largest share of the vaccines market. The segment held the dominant share in the market owing to various factors such increased pneumococcal disease cases, with a rising government investment in vaccination programs.

“Asia Pacific region is likely to grow at a faster pace in the vaccines market.”
The vaccines market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by companies that are upping their investments in Asia-Pacific region, benefiting from increased government support for vaccine development, rising healthcare expenditure in Asian countries, emergence & re-emergence of contagious disease and rising disposable income.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80%, and Demand Side - 20%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4% and Africa -1%
List of Companies Profiled in the Report:
• GSK plc (UK)
• Merck & Co., Inc. (US)
• Pfizer, Inc. (US)
• Sanofi (France)
• CSL (Australia)
• Emergent (US)
• Johnson & Johnson Services Inc. (US)
• AstraZeneca (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Panacea Biotec (India)
• Biological E. Limited (India)
• Bharat Biotech (India)
• Novavax (US)
• Inovio Pharmaceuticals (US)
• Sinovac (China)
• Incepta Pharmaceuticals (Bangladesh)
• Valneva SE (France),
• VBI Vaccines Inc. (US)
• Bio Farma (Indonesia)
• FSUE NPO Microgen (Russia)
• Zhi fei Biological (China)
• Indian Immunologicals Ltd (India)
Research Coverage:
This report provides a detailed picture of the vaccines market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (stringnent regulatory processes, vaccine supply shortage, frequent product recall) are influencing the growth of clinical trial supplies market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccines market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（pediatric）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（pediatric）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?